Advertisement
Research Article

Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium falciparum Circumsporozoite Protein

  • Aric L. Gregson,

    Affiliation: Department of Medicine and Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

    Current address: Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America,

    X
  • Giane Oliveira,

    Affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America

    Current address: Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

    X
  • Caroline Othoro,

    Affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America

    X
  • J. Mauricio Calvo-Calle,

    Affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America

    Current address: Department of Pathology, University of Massachusetts School of Medicine, Worcester, Massachusetts, United States of America

    X
  • George B. Thorton,

    Affiliation: Apovia, Inc., San Diego, California, United States of America

    X
  • Elizabeth Nardin,

    Affiliation: Department of Medical and Molecular Parasitology, New York University School of Medicine, New York, New York, United States of America

    X
  • Robert Edelman mail

    *E-mail: redelman@medicine.umaryland.edu.

    Affiliation: Department of Medicine and Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

    X
  • Published: February 06, 2008
  • DOI: 10.1371/journal.pone.0001556

Reader Comments (2)

Post a new comment on this article

Referee comments: Referee 1

Posted by PLoS_ONE_Group on 08 Feb 2008 at 22:27 GMT

Referee 1's review:

I think the changes made have improved the manuscript, and I accept the authors reasons for leaving parts of the manuscript unchanged where they disagreed with my suggestions.

There is, however, one exception. The abstract states that "We compared saline and Alhydrogel (aluminum hydroxide)-adjuvanted vaccine formulations at three ICC-1132 dose levels...".

This implies that both the saline and alhydrogel adjuvant vaccinations were given at each dose level. If I read the paper correctly, the vaccine was unstable in saline and so this was only given at the lower dose. This isn't the impression one would get reading the abstract, and I think this should be corrected. I would suggest that the instability of the vaccine in saline is so important it should at least be mentioned in the abstract, and that would clarify this impression.

***********
N.B. These are the comments made by the referee when reviewing an earlier version of this paper. Prior to publication the manuscript has been revised in light of these comments and to address other editorial requirements.